Commercial Physical & Biological Research Industry - SEC Form 4 Insider Trading Screener
Services Sector - Engineering, Accounting, Research, Management Services - Commercial Physical & Biological Research
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Share Price |
Shares Traded |
Shares Owned |
Own chg |
Value Traded |
1d ret |
1w ret |
1m ret |
6m ret |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2018-04-18 | IQV | Iqvia Holdings Inc. | Evanisko Michael J | Dir | S - Sale | $100.00 | -815 | 6,101 | -12% | -$81,500 | ||||||
| D | 2018-04-16 | EXEL | Exelixis, Inc. | Wyszomierski Jack L | Dir | S - Sale+OE | $20.25 | -14,959 | 93,844 | -14% | -$302,920 | |||||
| D | 2018-04-16 | EXEL | Exelixis, Inc. | Garber Alan M | Dir | S - Sale+OE | $20.25 | -15,000 | 61,329 | -20% | -$303,750 | |||||
| M | 2018-04-16 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.41 | -39,172 | 2,046,313 | -2% | -$133,522 | |||||
| DM | 2018-04-12 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale+OE | $3.39 | -78,045 | 2,085,485 | -4% | -$264,262 | |||||
| D | 2018-04-11 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $20.78 | -90,000 | 318,604 | -22% | -$1,870,200 | |||||
2018-04-12 | EXAS | Exact Sciences Corp | Zanotti Katherine S | Dir | S - Sale | $45.00 | -7,232 | 105,814 | -6% | -$325,440 | ||||||
| M | 2018-04-10 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.43 | -44,012 | 2,120,318 | -2% | -$151,014 | |||||
2018-04-10 | EXAS | Exact Sciences Corp | Doyle James Edward | Dir | S - Sale | $40.97 | -3,098 | 35,181 | -8% | -$126,925 | ||||||
2018-04-10 | EXAS | Exact Sciences Corp | Carey Thomas D. | Dir | S - Sale | $39.73 | -8,448 | 52,410 | -14% | -$335,630 | ||||||
| M | 2018-04-03 | ELOX | Eloxx Pharmaceuticals, Inc. | Shabtai Gilad | 10% | P - Purchase | $9.46 | +8,300 | 3,276,770 | 0% | +$78,545 | |||||
| D | 2018-04-02 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $28.75 | -3,000 | 32,600 | -8% | -$86,250 | |||||
| D | 2018-04-02 | EXAS | Exact Sciences Corp | Coward D Scott | SVP, GC | S - Sale+OE | $40.12 | -2,122 | 70,690 | -3% | -$85,124 | |||||
2018-03-29 | ELOX | Eloxx Pharmaceuticals, Inc. | Shabtai Gilad | 10% | P - Purchase | $9.64 | +4,500 | 3,268,470 | 0% | +$43,380 | ||||||
| D | 2018-03-29 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $29.50 | -100 | 32,600 | 0% | -$2,950 | |||||
| D | 2018-03-28 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $28.87 | -4,068 | 32,600 | -11% | -$117,441 | |||||
2018-03-26 | ELOX | Eloxx Pharmaceuticals, Inc. | Avnur Zafrira | Dir | P - Purchase | $9.49 | +2,000 | 2,263 | +760% | +$18,980 | ||||||
| DM | 2018-03-26 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $28.66 | -4,991 | 32,600 | -13% | -$143,043 | |||||
| DM | 2018-03-22 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $30.15 | -356 | 32,600 | -1% | -$10,732 | |||||
2018-03-23 | ELOX | Eloxx Pharmaceuticals, Inc. | Ward Robert | CEO | P - Purchase | $8.99 | +10,000 | 10,000 | New | +$89,900 | ||||||
2018-03-23 | ELOX | Eloxx Pharmaceuticals, Inc. | Weaver Gregory L | CFO | P - Purchase | $8.56 | +4,500 | 4,500 | New | +$38,520 | ||||||
| M | 2018-03-21 | ELOX | Eloxx Pharmaceuticals, Inc. | Nussbaum Ran | Dir | P - Purchase | $7.76 | +12,600 | 7,615,249 | 0% | +$97,830 | |||||
| M | 2018-03-21 | ELOX | Eloxx Pharmaceuticals, Inc. | Kariv Tomer | Dir | P - Purchase | $7.76 | +12,600 | 7,615,249 | 0% | +$97,830 | |||||
| M | 2018-03-21 | ELOX | Eloxx Pharmaceuticals, Inc. | Pontifax Management 4 G.P. (2015) Ltd. | 10% | P - Purchase | $7.76 | +12,600 | 427,063 | +3% | +$97,830 | |||||
2018-03-21 | ELOX | Eloxx Pharmaceuticals, Inc. | Avnur Zafrira | Dir | P - Purchase | $7.60 | +263 | 263 | New | +$1,999 | ||||||
| DM | 2018-03-20 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $31.13 | -5,612 | 32,600 | -15% | -$174,717 | |||||
| D | 2018-03-16 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $31.74 | -2,383 | 32,600 | -7% | -$75,642 | |||||
| DM | 2018-03-14 | IQV | Iqvia Holdings Inc. | Parks Robert | SVP, Controller | S - Sale+OE | $105.73 | -896 | 2,066 | -30% | -$94,734 | |||||
| DM | 2018-03-09 | EXAS | Exact Sciences Corp | Lidgard Graham Peter | Chief Science Officer | S - Sale+OE | $51.98 | -14,550 | 206,289 | -7% | -$756,271 | |||||
| D | 2018-03-12 | EXAS | Exact Sciences Corp | Coward D Scott | SVP, GC | S - Sale+OE | $52.19 | -2,708 | 68,124 | -4% | -$141,341 | |||||
| D | 2018-03-12 | EXAS | Exact Sciences Corp | Conroy Kevin T | Pres, CEO | S - Sale+OE | $52.19 | -11,459 | 973,208 | -1% | -$598,091 | |||||
| D | 2018-03-12 | EXAS | Exact Sciences Corp | Arora Maneesh | COO | S - Sale+OE | $52.19 | -5,295 | 658,613 | -1% | -$276,367 | |||||
| D | 2018-03-09 | CRL | Charles River Laboratories International Inc | Milne George M Jr | Dir | S - Sale+OE | $115.00 | -7,740 | 30,020 | -20% | -$890,100 | |||||
2018-03-07 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $2.92 | +1,360 | 1,018,210 | 0% | +$3,971 | ||||||
| D | 2018-03-05 | EXEL | Exelixis, Inc. | Feldbaum Carl B | Dir | S - Sale+OE | $23.88 | -11,000 | 34,733 | -24% | -$262,680 | |||||
| D | 2018-03-05 | EXEL | Exelixis, Inc. | Cohen Charles | Dir | S - Sale+OE | $24.23 | -15,000 | 248,180 | -6% | -$363,450 | |||||
| D | 2018-03-06 | EXEL | Exelixis, Inc. | Marchesi Vincent T | Dir | S - Sale+OE | $24.73 | -15,000 | 125,913 | -11% | -$370,950 | |||||
| D | 2018-03-06 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale+OE | $110.00 | -24,008 | 352,178 | -6% | -$2,640,880 | |||||
| D | 2018-03-06 | CRL | Charles River Laboratories International Inc | Girshick Birgit | Corporate EVP | S - Sale+OE | $109.10 | -9,893 | 22,977 | -30% | -$1,079,343 | |||||
2018-03-05 | IQV | Iqvia Holdings Inc. | Evanisko Michael J | Dir | S - Sale | $100.00 | -816 | 6,916 | -11% | -$81,600 | ||||||
2018-03-06 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $2.73 | +1,450 | 1,016,850 | 0% | +$3,959 | ||||||
2018-03-05 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | P - Purchase | $2.63 | +1,500 | 1,015,400 | 0% | +$3,945 | ||||||
2018-03-02 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Dir, Pres, CEO | P - Purchase | $2.41 | +1,650 | 1,013,900 | 0% | +$3,977 | ||||||
| D | 2018-03-02 | EXEL | Exelixis, Inc. | Papadopoulos Stelios | Dir | S - Sale+OE | $24.05 | -15,000 | 1,034,314 | -1% | -$360,750 | |||||
| D | 2018-03-02 | EXEL | Exelixis, Inc. | Willsey Lance | Dir | S - Sale+OE | $23.91 | -30,000 | 468,273 | -6% | -$717,300 | |||||
| D | 2018-02-28 | EXEL | Exelixis, Inc. | Haley Patrick J. | SVP, Commercial | S - Sale+OE | $27.13 | -45,029 | 147,130 | -23% | -$1,221,637 | |||||
| D | 2018-02-28 | EXEL | Exelixis, Inc. | Poste George | Dir | S - Sale+OE | $26.26 | -15,000 | 83,398 | -15% | -$393,900 | |||||
| ADM | 2018-02-26 | EXAS | Exact Sciences Corp | Lidgard Graham Peter | Chief Science Officer | S - Sale+OE | $43.10 | -39,884 | 206,289 | -16% | -$1,718,847 | |||||
| D | 2018-02-28 | PRTX | Protalex Inc | Kling Arnold P | Pres, 10% | P - Purchase | $1.20 | +18,557,805 | 41,138,954 | +82% | +$22,269,366 | |||||
2018-02-28 | CRL | Charles River Laboratories International Inc | Smith David Ross | Corporate EVP, CFO | S - Sale | $108.43 | -100 | 13,103 | -1% | -$10,843 | ||||||
| D | 2018-02-28 | CRL | Charles River Laboratories International Inc | Smith David Ross | Corporate EVP, CFO | S - Sale+OE | $107.90 | -5,240 | 13,203 | -28% | -$565,414 | |||||
2018-02-28 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $108.47 | -2,102 | 352,178 | -1% | -$227,995 | ||||||
2018-02-28 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $108.24 | -4,398 | 306,042 | -1% | -$476,046 | ||||||
2018-02-28 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $108.03 | -5,102 | 310,440 | -2% | -$551,176 | ||||||
2018-02-28 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $107.81 | -5,098 | 315,542 | -2% | -$549,639 | ||||||
| D | 2018-02-28 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale+OE | $107.39 | -3,372 | 320,640 | -1% | -$362,113 | |||||
| D | 2018-02-27 | CRL | Charles River Laboratories International Inc | Smith David Ross | Corporate EVP, CFO | S - Sale+OE | $108.10 | -2,158 | 14,078 | -13% | -$233,283 | |||||
2018-02-27 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $108.41 | -4,707 | 354,442 | -1% | -$510,282 | ||||||
2018-02-27 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $108.15 | -7,067 | 308,647 | -2% | -$764,280 | ||||||
2018-02-27 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $107.91 | -5,993 | 315,714 | -2% | -$646,703 | ||||||
| D | 2018-02-27 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale+OE | $107.66 | -3,810 | 321,707 | -1% | -$410,199 | |||||
| D | 2018-02-27 | EXAS | Exact Sciences Corp | Arora Maneesh | COO | S - Sale+OE | $44.10 | -5,512 | 652,633 | -1% | -$243,068 | |||||
| DM | 2018-02-26 | EXAS | Exact Sciences Corp | Lidgard Graham Peter | Chief Science Officer | S - Sale+OE | $42.88 | -35,025 | 211,148 | -14% | -$1,501,960 | |||||
2018-02-28 | SRNE | Sorrento Therapeutics, Inc. | Ng George K | See Remarks | P - Purchase | $9.95 | +90,000 | 407,935 | +28% | +$895,500 | ||||||
2018-02-28 | SRNE | Sorrento Therapeutics, Inc. | Ji Henry | See Remarks | P - Purchase | $9.95 | +64,600 | 4,348,501 | +2% | +$642,770 | ||||||
| D | 2018-02-27 | EXAS | Exact Sciences Corp | Conroy Kevin T | Pres, CEO | S - Sale+OE | $44.10 | -9,085 | 960,267 | -1% | -$400,630 | |||||
| D | 2018-02-26 | IQV | Iqvia Holdings Inc. | Erlinger III James H | See Remarks | S - Sale+OE | $100.00 | -10,000 | 13,494 | -43% | -$1,000,000 | |||||
2018-02-26 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $108.81 | -900 | 354,442 | 0% | -$97,929 | ||||||
2018-02-26 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $108.43 | -4,429 | 307,014 | -1% | -$480,232 | ||||||
2018-02-26 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $107.86 | -5,269 | 311,443 | -2% | -$568,287 | ||||||
2018-02-26 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $107.31 | -3,999 | 316,712 | -1% | -$429,135 | ||||||
2018-02-26 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $107.00 | -5,727 | 320,711 | -2% | -$612,779 | ||||||
| D | 2018-02-26 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale+OE | $106.69 | -4,800 | 326,438 | -1% | -$512,123 | |||||
2018-02-26 | CRL | Charles River Laboratories International Inc | Smith David Ross | Corporate EVP, CFO | S - Sale | $108.53 | -319 | 14,078 | -2% | -$34,620 | ||||||
| D | 2018-02-26 | CRL | Charles River Laboratories International Inc | Smith David Ross | Corporate EVP, CFO | S - Sale+OE | $107.35 | -3,868 | 14,615 | -21% | -$415,224 | |||||
| DM | 2018-02-23 | EXAS | Exact Sciences Corp | Lidgard Graham Peter | Chief Science Officer | S - Sale+OE | $40.44 | -27,428 | 218,936 | -11% | -$1,109,266 | |||||
| D | 2018-02-26 | EXAS | Exact Sciences Corp | Elliott Jeffrey Thomas | CFO | S - Sale+OE | $42.34 | -2,982 | 21,793 | -12% | -$126,252 | |||||
| D | 2018-02-26 | EXAS | Exact Sciences Corp | Coward D Scott | SVP, GC | S - Sale+OE | $42.34 | -4,420 | 52,699 | -8% | -$187,134 | |||||
| D | 2018-02-26 | EXAS | Exact Sciences Corp | Conroy Kevin T | Pres, CEO | S - Sale+OE | $42.34 | -25,319 | 949,327 | -3% | -$1,071,956 | |||||
| D | 2018-02-26 | EXAS | Exact Sciences Corp | Arora Maneesh | COO | S - Sale+OE | $42.34 | -12,352 | 645,995 | -2% | -$522,959 | |||||
2018-02-21 | INCY | Incyte Corp | Gryska David W | EVP, CFO | S - Sale | $85.56 | -1,952 | 10,970 | -15% | -$167,013 | ||||||
2018-02-21 | INCY | Incyte Corp | Huber Reid M | EVP, Chief Scientific Officer | S - Sale | $85.55 | -1,958 | 35,183 | -5% | -$167,507 | ||||||
2018-02-21 | CRL | Charles River Laboratories International Inc | Barbo William D | Corporate EVP, CCO | S - Sale | $108.08 | -2,320 | 19,156 | -11% | -$250,741 | ||||||
2018-02-16 | BASI | Bioanalytical Systems Inc | Downing Philip A | SVP, Preclinical Srvcs. | P - Purchase | $1.46 | +5,000 | 15,765 | +46% | +$7,300 | ||||||
2018-02-16 | CRL | Charles River Laboratories International Inc | Smith David Ross | Corporate EVP, CFO | S - Sale | $109.07 | -3,639 | 11,671 | -24% | -$396,899 | ||||||
| A | 2017-08-14 | CRL | Charles River Laboratories International Inc | Smith David Ross | Corporate EVP, CFO | S - Sale | $97.86 | -1,303 | 15,310 | -8% | -$127,508 | |||||
2018-02-15 | CRL | Charles River Laboratories International Inc | Foster James C | COB, Pres, CEO | S - Sale | $107.50 | -46 | 343,123 | 0% | -$4,945 | ||||||
| D | 2018-02-15 | NRCIA | National Research Corp | Hays Michael D. | CEO | S - Sale+OE | $19.31 | -5,261,410 | 139,182 | -97% | -$101,597,827 | |||||
2018-02-15 | NRCIA | National Research Corp | Amandla Mk Trust | 10% | P - Purchase | $19.31 | +5,494,440 | 7,378,645 | +292% | +$106,097,636 | ||||||
| D | 2018-02-15 | CRL | Charles River Laboratories International Inc | Chubb Stephen D | Dir | S - Sale+OE | $108.69 | -2,872 | 33,589 | -8% | -$312,172 | |||||
| D | 2018-02-13 | PIRS | Pieris Pharmaceuticals, Inc. | Orbimed Advisors LLC | 10% | S - Sale+OE | $8.98 | -7,897 | 49,270 | -14% | -$70,915 | |||||
| D | 2018-02-09 | EXAS | Exact Sciences Corp | Conroy Kevin T | Pres, CEO | S - Sale+OE | $45.72 | -101,488 | 920,241 | -10% | -$4,640,272 | |||||
| E | 2017-12-19 | HPPI | Hedgepath Pharmaceuticals, Inc. | Cross Stefan | Dir | P - Purchase | $0.27 | +600,000 | 0 | -100% | +$162,660 | |||||
| E | 2017-12-19 | HPPI | Hedgepath Pharmaceuticals, Inc. | Mayne Pharma Ventures Pty Ltd | 10% | P - Purchase | $0.27 | +600,000 | 198,106,132 | 0% | +$162,660 | |||||
| DM | 2018-02-06 | SRNE | Sorrento Therapeutics, Inc. | Abg Management Ltd | 10% | S - Sale+OE | $6.85 | -662,912 | 7,088,903 | -9% | -$4,542,234 | |||||
| D | 2018-02-05 | SRNE | Sorrento Therapeutics, Inc. | Abg Management Ltd | 10% | S - Sale+OE | $8.00 | -70,721 | 7,751,815 | -1% | -$566,037 | |||||
| DM | 2018-01-29 | SRNE | Sorrento Therapeutics, Inc. | Abg Management Ltd | 10% | S - Sale+OE | $7.64 | -310,000 | 7,822,536 | -4% | -$2,368,864 | |||||
| D | 2018-01-25 | NRCIA | National Research Corp | Hays Michael D. | CEO, 10% | S - Sale+OE | $39.03 | -1,602,399 | 5,400,592 | -23% | -$62,541,633 | |||||
| M | 2018-01-23 | SRNE | Sorrento Therapeutics, Inc. | Asia Pacific Medtech (Bvi) Ltd | 10% | S - Sale | $7.56 | -684,288 | 8,617,513 | -7% | -$5,175,690 | |||||
| D | 2018-01-23 | EXAS | Exact Sciences Corp | Conroy Kevin T | Pres, CEO | S - Sale+OE | $50.49 | -110,439 | 920,241 | -11% | -$5,575,961 |
Real-time CSV? Options? Alerts? Contact us!
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |